Glaucoma Insights

MIGS with OMNI system linked with diminished diurnal IOP fluctuations, a risk factor for glaucoma progression

The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.

Pharmaceutical company files IND application with FDA for glaucoma candidate

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

Study highlights favorable two-year outcomes of standalone use of surgical system on mild to moderate open-angle glaucoma

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.

Studying glaucoma epidemiology at the center of the Earth

January 30, 2021

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.